The result marks the third consecutive grant cycle in which NRG Oncology has achieved the exceptional score. In the NCI review framework, such scores reflect a judgment that a research program has outstanding scientific merit, a clear potential for meaningful clinical impact, and the infrastructure needed to deliver its proposed work. For a cooperative clinical research group, the evaluation encompasses far more than laboratory discovery. Reviewers assess the organization’s ability to design statistically rigorous trials, recruit patients across multiple institutions, manage complex data, integrate biological specimens, monitor treatment safety, and translate results into clinical practice. NRG Oncology’s renewal therefore represents both continued federal investment and a strong endorsement of its research model.

“This is the third grant cycle in a row that NRG Oncology has received an exceptional score during the grant application review process,” said Quynh Thu Le, MD, an NRG Oncology Group Chair, Chair of the Department of Radiation Oncology at Stanford University, and Co-Director of the Radiation Biology Program at the Stanford Cancer Institute. She also chairs the NRG Oncology Board of Directors. Le described the recognition as an acknowledgment of the collective effort required to improve outcomes for people affected by cancer. In modern oncology, advances rarely result from a single institution or discipline. They emerge from coordinated studies that combine clinical expertise with molecular biology, imaging, radiation science, surgery, pathology, biostatistics, and patient-centered research.

NRG Oncology’s renewed mission focuses on adult patients with sex-specific malignancies, including breast, gynecologic, and prostate cancers, as well as people with localized or locally advanced cancers. These diseases occupy an important space in cancer research because treatment decisions often depend on the biological behavior of a tumor, its anatomical extent, the risk of recurrence, and the patient’s individual health profile. Localized cancers may be curable, but unnecessary treatment can cause lasting harm, including infertility, cardiovascular complications, neurological effects, sexual dysfunction, or chronic tissue damage. NRG Oncology’s trials seek to identify which patients require intensive treatment, which can safely receive less, and how emerging therapies can be integrated without compromising disease control.

A central feature of the group’s scientific strategy is risk stratification, the process of separating patients into clinically meaningful categories according to the likelihood that their cancer will return or progress. Researchers use conventional clinical variables, such as tumor stage and grade, alongside biomarkers that reveal genetic, molecular, or immune characteristics of the disease. This information can be incorporated into algorithms that guide treatment intensity and duration. For example, a molecular signature may indicate that a tumor is biologically aggressive even when it appears limited on imaging, or it may identify a patient whose cancer is unlikely to benefit from prolonged therapy. Testing these approaches in prospective, multi-institutional trials is essential because an algorithm must demonstrate reproducible clinical benefit, not merely statistical association.

The group is also applying emerging knowledge in therapeutics to early- and late-phase clinical trials. These studies may evaluate targeted medicines designed to interfere with specific signaling pathways, immunotherapies that alter the interaction between tumors and the immune system, or combinations intended to overcome treatment resistance. In localized and locally advanced disease, the timing of systemic therapy can be as important as the drug itself. Investigators may test whether treatment given before surgery or radiation can shrink a tumor, eliminate microscopic disease, or provide an early indication of sensitivity. Other trials examine whether maintenance therapy can prevent recurrence after definitive treatment. Because these questions involve both survival and long-term quality of life, they require carefully controlled designs and prolonged follow-up.

Radiation oncology, surgery, and medical imaging are additional areas in which NRG Oncology is testing new technologies through multi-institutional research. Advances in image guidance can allow clinicians to locate tumors and vulnerable organs with greater precision, while modern radiation techniques can shape dose distributions around complex anatomy. Surgical trials may evaluate less invasive procedures or strategies that preserve normal function without reducing cancer control. Imaging research can explore whether functional or molecular scans provide information beyond standard anatomical pictures. Yet technological sophistication alone does not establish clinical value. NRG Oncology’s randomized trials are intended to determine whether these innovations improve survival, reduce toxic effects, enhance quality of life, or make treatment more efficient and accessible.

“The overall impact of NRG Oncology is high, with the potential to markedly enhance the quality of clinical trials based on the outstanding progress during the current funding period,” NCI grant reviewers wrote, highlighting the organization’s continued emphasis on science-driven and molecularly guided therapeutic studies. Their assessment also recognized the group’s focus on sex-driven, rare, and localized or locoregionally advanced cancers. These categories include diseases for which individual hospitals may struggle to enroll enough participants to answer important questions. By connecting hundreds of centers, cooperative groups can assemble patient populations large enough to compare treatments reliably, investigate uncommon tumor features, and identify differences in outcomes across diverse communities.

The scale of that network is central to the organization’s work. NRG Oncology was founded in 2012 through the integration of research programs associated with the National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group. It now brings together more than 1,300 research sites worldwide, with most located in the United States and Canada. Its investigators include medical and radiation oncologists, surgeons, physicists, pathologists, statisticians, imaging specialists, and other experts. Patient advocates also participate in the research process, helping shape questions that matter to people living with cancer and drawing attention to outcomes that may not be captured by survival statistics alone. The organization’s studies are supported primarily by NCI grants and form part of the federally funded NCTN, one of the world’s largest publicly supported infrastructures for cancer clinical research.

Robert Mannel, MD, an NRG Oncology Group Chair and Director of the Stephenson Cancer Center at the University of Oklahoma, emphasized that the renewal depended on the contributions of member sites, researchers, advocates, staff, and—most importantly—the patients who enroll in trials. Norman Wolmark, MD, the organization’s grant contact principal investigator and a professor of surgery at the University of Pittsburgh, said the exceptional score and the strengths identified by reviewers indicate that NRG Oncology is positioned to build on its recent achievements. Over the next six years, the group will use the new funding to pursue trials intended to make cancer treatment more precise: matching therapies to tumor biology, limiting unnecessary exposure, improving the use of radiation and surgery, and producing evidence that can move rapidly from research centers into everyday care. For patients, the significance of the award will ultimately be measured not by the grant itself, but by whether the studies it enables help more people live longer and with fewer consequences of cancer and its treatment.

Subject of Research: NRG Oncology’s federally funded cancer clinical-trial and translational-research program, including molecularly guided treatment, risk stratification, radiation oncology, surgery, imaging, and sex-specific and localized or locally advanced cancers.

News Publication Date: Not provided. The renewed six-year grant cycle began March 1, 2026.

Web References: NRG Oncology, www.nrgoncology.org

Keywords: NRG Oncology, National Cancer Institute, National Clinical Trials Network, cancer research, clinical trials, oncology, molecular biomarkers, risk stratification, radiation oncology, breast cancer, gynecologic cancer, prostate cancer, localized cancer, translational research

Each year, over 80,000 individuals aged between 15 and 39 receive a cancer diagnosis, and currently, more than two million young cancer survivors reside in the United States alone. This demographic faces a complex constellation of issues as they transition from treatment to survivorship. Unlike pediatric or older adult cancer patients, AYAs confront a distinct set of psychosocial and physiological stressors, including the interruption of critical life milestones such as educational advancement, career initiation, and family planning. Their post-treatment landscape is shaped both by the biological repercussions of the disease and its treatment, and by the broader societal ramifications of their experience.

Leading this ambitious endeavor is Dr. Shoshana Rosenberg, an associate professor of population health sciences at Weill Cornell Medicine. Dr. Rosenberg emphasizes the pressing need to understand the particular needs of young survivors, which diverge substantially from those of other age groups. The study seeks to garner direct insights from patients to inform and refine clinical care delivery. By focusing on patient-reported experiences and real-world outcomes, the research aims to translate these findings into more empathetic and effective healthcare strategies tailored for the AYA population.

Central to the study’s methodology is the creation of a meticulously assembled cohort of 2,000 adolescent and young adult cancer survivors located in New York City. This diverse cohort will be monitored longitudinally to evaluate both immediate and delayed consequences of novel therapeutic approaches, including biological agents and immunotherapies now increasingly prominent in oncology. Unlike traditional chemotherapy and radiation, these newer treatments have complex profiles regarding long-term toxicity and survivorship outcomes. Documenting these effects will provide critical data to delineate survivorship patterns unique to modern treatment paradigms.

One distinctive aspect of this research is its comprehensive approach to the myriad challenges AYAs face post-treatment. The study places considerable emphasis on sensitive yet consequential issues such as fertility preservation and sexual health, acknowledging that cancer and its treatments can profoundly impact reproductive potential and intimacy. In tandem, the financial burdens incurred by young survivors are also scrutinized, recognizing that the economic strain of cancer care can exacerbate psychological distress and hinder access to follow-up services. By addressing these interconnected domains, the research fosters a holistic understanding of survivorship.

The project deploys an innovative mobile application designed expressly for this digitally adept generation to facilitate seamless communication between researchers and participants. This app will enable survivors to regularly complete surveys and provide health updates over the study period. Moreover, it is equipped to collect sensor-derived data related to physical activity and sleep patterns, delivering an unprecedented window into daily functioning and overall well-being through passive monitoring. This multi-modal data collection promises to enrich the characterization of health trajectories following cancer treatment.

Beyond patient self-report and passive sensor data, the study integrates biological sample collection and access to electronic medical records (EMRs). Leveraging EMRs allows for real-time clinical data assimilation, including lab results and treatment history, strengthening the robustness of longitudinal analyses. Biological samples may aid in identifying biomarkers predictive of late-onset complications, offering the tantalizing possibility of preemptive interventions. Such integrative data strategies exemplify the movement toward precision medicine in oncology survivorship, aiming to tailor supportive care based on individual risk profiles.

An equally important goal of the project is to translate findings into actionable interventions that can preempt or mitigate adverse long-term health outcomes. By identifying risk factors for sequelae such as cardiotoxicity, secondary malignancies, or psychological distress, the research hopes to enable earlier clinical interventions. Furthermore, the study seeks to dismantle barriers of accessibility to supportive care services, enhancing equity in survivorship care for AYAs from diverse socioeconomic and cultural backgrounds. The intention is to promote not only survival but quality of life and functional recovery.

The mobile platform also holds potential beyond data collection—serving as a conduit for disseminating supportive care resources and fostering a sense of community among participants. Social isolation is a common and often overlooked plight for young survivors, and digital connectivity can offer critical psychosocial support. By creating virtual spaces for peer engagement and information exchange, the study envisions reinforcement of resilience and empowerment. This approach aligns with emerging trends in digital health interventions aimed at chronic disease management and mental health support.

Dr. Rosenberg expresses hope that this pioneering research will illuminate previously unanswered questions surrounding the AYA cancer survivor experience. The study is poised to inform communication strategies between healthcare providers and patients, ensuring that the unique concerns of young survivors are acknowledged and addressed effectively throughout the continuum of care. Improving dialogue and understanding within clinical encounters is fundamental to fostering shared decision-making and personalized survivorship planning.

Joining Dr. Rosenberg are co-principal investigators Dr. Danielle Friedman, an attending physician at Memorial Sloan Kettering Cancer Center, and Dr. Jeanine Genkinger, an associate professor of epidemiology at Columbia University Mailman School of Public Health. Their combined expertise in clinical oncology, epidemiology, and population health sciences bolsters the interdisciplinary nature of this comprehensive research initiative. Together, the team aims to bridge gaps between clinical research and practical support mechanisms for AYAs battling the sequelae of cancer and its treatment.

This study reflects a broader paradigm shift in oncology, moving from a sole focus on disease eradication toward a more nuanced understanding of survivorship and quality of life. By harnessing cutting-edge technology and cross-disciplinary collaboration, the project exemplifies future directions for cancer research and care delivery. The integration of patient engagement, digital health tools, biomarker discovery, and social determinants of health marks an important evolution in addressing the needs of historically overlooked populations.

Ultimately, the funding and research efforts spearheaded by Weill Cornell Medicine and collaborators aspire to create a replicable model for AYA cancer survivorship care. Insights garnered from this New York City cohort could catalyze policy changes, guide healthcare infrastructure development, and inspire similar studies nationally and globally. As survival rates improve across cancer types, the imperative to optimize long-term outcomes and holistic well-being for young survivors stands as a defining challenge—and opportunity—of modern oncology.

Subject of Research: Adolescent and Young Adult (AYA) Cancer Survivorship and Supportive Care Development

Article Title: Innovative Research Unveils the Hidden Struggles of Young Cancer Survivors: A Five-Year Study at Weill Cornell Medicine

News Publication Date: Not specified

Web References:

• Dr. Shoshana Rosenberg’s Faculty Profile, Weill Cornell
• Dr. Danielle Friedman, Memorial Sloan Kettering Cancer Center
• Dr. Jeanine Genkinger, Columbia University Mailman School of Public Health

Image Credits: Weill Cornell Medicine

Keywords: Cancer, Adolescent and Young Adult Survivors, Cancer Survivorship, Immunotherapy, Biological Treatments, Long-term Effects, Fertility Concerns, Financial Stress, Digital Health, Mobile Applications, Biomarkers, Supportive Care, Patient-Centered Research

The research pivots around the concept that cancer cells are, in effect, lipid-addicted. As explained by Dr. Keren Hilgendorf, an assistant professor of biochemistry and Investigator at the Huntsman Cancer Institute, lipids have been underestimated in their role within the obesity-cancer nexus. The study reveals that triple-negative breast cancer cells exploit the abundance of fatty acids circulating in the bloodstream of obese individuals to sustain and propagate their growth. The implication is profound: controlling lipid levels could directly influence tumor aggressiveness.

Hyperlipidemia, characterized by elevated circulating lipids, emerges as a critical metabolic state underlying this phenomenon. Dr. Amandine Chaix, who specializes in nutrition and integrative physiology, explained that lipids are essential components of the cell’s surface membrane, constituting the building blocks necessary for cellular replication. Their presence in high concentrations essentially provides the raw materials needed for cancer cells to proliferate rapidly, reinforcing the concept that lipid abundance directly correlates with tumor acceleration.

The experimental strategy employed involved high-fat diet mouse models alongside genetically engineered mice exhibiting hyperlipidemia independent of other obesity markers like hyperglycemia or hyperinsulinemia. Strikingly, these models demonstrated that elevated lipid profiles alone sufficed to expedite tumor progression. Such a finding suggests that targeting lipid metabolism could be a viable independent therapeutic axis distinct from glucose or insulin signaling interventions.

Furthermore, when lipid levels were experimentally reduced even in the presence of high glucose and insulin, tumor growth significantly decelerated. This impactful observation suggests potential clinical applicability, where lipid-lowering agents, already widely used for cardiovascular indications, might be repurposed to aid breast cancer treatment. The translation of these results from murine models to humans will require extensive validation, but they lay a promising groundwork for future clinical trials.

The study also raises caution regarding dietary recommendations for breast cancer patients with obesity. Popular weight loss strategies, such as ketogenic diets high in fat and low in carbohydrates, may inadvertently exacerbate tumor growth by increasing lipid availability. Dr. Greg Ducker, biochemistry assistant professor and Huntsman investigator, emphasizes that individualized medical guidance is essential before adopting such diets. The complex metabolic landscape in cancer requires a more nuanced understanding than a one-size-fits-all approach.

Currently, obesity is recognized as a significant risk factor for breast cancer incidence and progression, but explicit guidelines on nutritional management remain scarce. These findings suggest that weight loss interventions for breast cancer patients should prioritize lipid management rather than merely caloric restriction or carbohydrate limitation. This paradigm shift could influence oncological dietetics profoundly, promoting lipid lowering as a cornerstone of adjunctive cancer therapy.

Beyond triple-negative breast cancer, the researchers hypothesize that lipid-driven tumor acceleration may extend to other cancer types prevalent among obese individuals, including ovarian and colorectal cancers. This broadens the potential impact of their work and warrants extensive exploration in diverse oncological contexts. Investigating how anti-lipid therapies interact with existing chemotherapy regimens could catalyze synergistic treatment modalities.

The research team is committed to dissecting the cellular mechanisms by which lipids are assimilated and utilized within cancer cells. Understanding these metabolic pathways at a molecular level may unlock additional therapeutic targets, potentially disrupting the lipid supply chain critical to tumor sustenance. Such insight will be paramount for designing interventions with precise metabolic specificity.

While the risks of high-fat diets in obesity-related breast cancer have been illuminated, the investigators note that ketogenic or similar diets might retain therapeutic value in other malignancies. This highlights the cancer-type specificity of metabolic vulnerabilities and underscores the necessity for detailed metabolic profiling in personalized oncology care.

Concluding, this seminal research highlights the pivotal role of lipids in obesity-accelerated triple-negative breast cancer growth and challenges the oncology community to rethink metabolic influences beyond glucose-centric paradigms. If validated clinically, lipid modulation could become a transformative adjunct to conventional breast cancer treatments, improving outcomes for patients burdened with obesity.

Their findings were recently published in the journal Cancer & Metabolism, authored by Renan Vieira and colleagues, underscoring the collaboration between metabolic science and cancer biology at the forefront of contemporary research. Supported by multiple grants from the National Cancer Institute and the Huntsman Cancer Foundation, this work exemplifies the interdisciplinary approach driving innovations in cancer therapeutics and prevention.

Subject of Research: The role of hyperlipidemia in driving tumor growth in obesity-associated triple-negative breast cancer

Article Title: Hyperlipidemia drives tumor growth in a mouse model of obesity-accelerated breast cancer growth

News Publication Date: 28-Aug-2025

Web References:

• DOI link to article
• Cancer & Metabolism Journal

References:

• Chaix, A., Hilgendorf, K., Ducker, G., et al. (2025). Hyperlipidemia drives tumor growth in a mouse model of obesity-accelerated breast cancer growth. Cancer & Metabolism. DOI: 10.1186/s40170-025-00407-0.

Image Credits: University of Utah Health

Keywords: Breast cancer, Obesity, Lipid metabolism, Hyperlipidemia, Triple-negative breast cancer, Cancer metabolism, Ketogenic diet, Tumor growth, Metabolic therapy, Obesity-associated cancers, Lipid-lowering drugs, Animal models

The Y chromosome, a defining genetic feature of males, harbors roughly 100 genes, many of which remain poorly characterized in the context of oncogenesis and immune regulation. Loss of the Y chromosome (LOY) in somatic cells, particularly immune cells circulating in the bloodstream, is a nonhereditary genetic alteration known to accumulate with age and has been epidemiologically linked to adverse clinical outcomes including heightened cancer mortality and cardiovascular disease. Yet, the mechanistic pathways bridging LOY to disease susceptibility have eluded clear definition until now.

Dr. Theodorescu’s laboratory has established foundational insights revealing that bladder tumors deficient in the Y chromosome exhibit markedly aggressive behavior, implicating a direct link between Y chromosome integrity and tumor biology. Crucially, his work extends beyond cancer cells themselves, demonstrating that LOY in immune cells compromises immune surveillance and anticancer responses, thereby creating a tumor-permissive microenvironment. This dual effect suggests that LOY may represent a convergent vulnerability exploited both by malignant cells and by immune evasion mechanisms.

Employing cutting-edge stem cell engineering alongside genetically precise mouse models, the study aims to dissect how specific losses of Y chromosome genetic content influence T cell functionality—a critical component of adaptive immunity—and subsequent tumor growth dynamics. By selectively inhibiting individual Y-linked genes, the researchers anticipate uncovering molecular pathways by which these genes normally constrain tumor aggressiveness and modulate immune efficacy.

A remarkable facet of this work includes the integration of high-throughput drug screening platforms designed to test thousands of compounds, encompassing FDA-approved medications and investigational drugs. This approach is intended to identify candidate therapies that can specifically target cancers lacking the Y chromosome or reinvigorate the function of immune cells compromised by LOY. Such pharmacogenomic insights hold the promise of personalized medicine refinement in male cancer patients affected by this chromosomal anomaly.

In addition to mechanistic elucidation, Theodorescu’s group is investigating the intricate interplay between LOY in tumor cells and the surrounding tumor microenvironment—a heterogeneous matrix of stromal cells, vasculature, and immune infiltrates that collectively influence tumor progression. Characterizing how LOY shapes this ecosystem could reveal novel biomarkers and therapeutic targets, ultimately improving clinical outcomes.

Significantly, the implications of this research transcend bladder cancer. The phenomenon of LOY is prevalent across multiple cancer types and aging populations, suggesting broad applicability of the findings. By establishing foundational biology of Y chromosome loss and its functional consequences, this initiative aspires to lay the groundwork for subsequent translational and clinical studies, ultimately enhancing cancer prevention, early detection, and treatment paradigms.

Moreover, the investigation will explore how Y chromosome loss in both cancerous and immune cells might affect responses to advanced immunotherapies such as chimeric antigen receptor (CAR) T-cell therapy. This modality customizes immune cells to recognize and attack tumors but has seen variable success in solid tumors like bladder cancer. Understanding the genetic and immunological context shaped by LOY may be key to optimizing these next-generation treatments.

“The loss of the Y chromosome in cancer biology represents an undiscovered country, rife with potential for breakthroughs,” Dr. Theodorescu explains. “Our findings so far underline the importance of Y chromosome genes in influencing cancer aggressiveness and immune function. We are optimistic that this research will translate into impactful clinical applications that improve patient survival and quality of life.”

As this endeavor progresses, the University of Arizona team remains committed to unraveling the complex genetic and immunological interplay driven by Y chromosome loss. By blending molecular genetics, immunology, and cancer biology with innovative experimental models and drug discovery techniques, the project exemplifies a holistic approach to confronting a mysterious yet significant factor in male health and oncology.

This research initiative stands as a testament to the evolving landscape of precision oncology, where genetic nuances once overlooked gain prominence as vital determinants of disease trajectory and therapeutic responsiveness. Future investigations stemming from this work may revolutionize our conception of sex chromosome biology in cancer and inspire targeted interventions that leverage the unique vulnerabilities conferred by chromosomal loss.

Ultimately, the fight against bladder cancer and related malignancies may benefit profoundly from insights derived from the Y chromosome’s secret life—transforming what was once thought to be genetic background noise into a symphony of potential breakthroughs in cancer control and immunotherapy.

Subject of Research:
Effects of Y chromosome loss in immune cells and bladder cancer progression

Article Title:
Unraveling the Role of Y Chromosome Loss in Bladder Cancer Aggressiveness and Immune Dysfunction

News Publication Date:
Not specified

Web References:
https://click.comms.arizona.edu/?qs=ed7a3852ad85ccfd672d000003381560526e597ac430d622de4cade72d68911e48a64ef6746d6fe547c238366627c7bc1641d34b6a3f0b43
https://click.comms.arizona.edu/?qs=ed7a3852ad85ccfdca68b037e975caf90a5c63d996c1832e8127caaeb9367e2e8a52c42300749882bd1e6297c6f28c4463f7ae7ddbe1feaf
https://click.comms.arizona.edu/?qs=ed7a3852ad85ccfde1cd5e7264b5172b31f0e3a37085ecfd38d6ab5d317f44aae56d7cb54a1d1cc7db2025142462f47910b8910dedb3fe15

Image Credits:
Illustration by Joshua Elz, University of Arizona Cancer Center

Keywords:
Cancer, Y chromosomes, Immune system, Chromosomes, Cancer risk

Targefrin represents a groundbreaking approach in targeting EphA2, or ephrin type-A receptor 2, a receptor tyrosine kinase that is markedly overexpressed in a variety of cancers including pancreatic, prostate, lung, breast, ovarian, and colorectal malignancies. EphA2’s aberrant expression facilitates cancer metastasis by promoting cancer cell migration from the primary tumor and enabling colonization of distant tissues. The ability of Targefrin to selectively degrade EphA2 offers a paradigm shift in controlling tumor progression and metastasis.

The molecule known as Targefrin was originally discovered in the laboratory of Maurizio Pellecchia, a renowned professor at the UCR School of Medicine and one of Armida Labs’ co-founders. Pellecchia’s pioneering work led to the conceptualization of Targefrin as a dimeric peptide mimetic designed to engage EphA2 in a unique mechanism of action. The IND-enabling studies will be overseen by Carlo Baggio, Armida Labs’ co-founder and chief technology officer, who serves as principal investigator for the grant.

Baggio highlighted that the laboratory’s multi-year focus on EphA2 has culminated in Targefrin’s evolution. “EphA2 is a key driver of pancreatic cancer aggressiveness,” he noted, “and elevated EphA2 expression is associated with dismal patient prognosis. Targefrin’s mechanism — effectively degrading EphA2 — has the potential to convert aggressive tumors into less invasive phenotypes.” The successful Phase I SBIR award of $600,000 laid the foundation for this current expanded research endeavor.

Delving into the biochemistry of Targefrin reveals a sophisticated molecular design inspired by nature’s own regulatory systems. The molecule is a dimeric peptide mimetic, structurally engineered to emulate ephrins—natural ligands of the EphA2 receptor. Through dimerization, Targefrin induces receptor clustering, a biological process that triggers internalization and degradation of EphA2 from the cancer cell surface. This targeted receptor downregulation disrupts the pro-oncogenic signaling cascade that EphA2 mediates in its ligand-independent, overexpressed state.

EphA2’s dualistic nature in cancer biology is critical to understanding Targefrin’s therapeutic rationale. Under normal physiological conditions, EphA2 interactions with ephrin ligands suppress tumorigenesis by inhibiting cell migration and proliferation. However, in many solid tumors, including pancreatic and prostate cancers, EphA2 is upregulated independently of its ligands, converting it into a pro-metastatic oncoprotein. This ligand-independent EphA2 promotes cellular motility, invasion, and establishment of metastatic niches, representing a formidable obstacle in cancer therapy. Targefrin’s ability to restore balance by mimicking ligand binding and triggering receptor degradation directly counteracts this pathological state.

The development pipeline for Targefrin involved an iterative chemical design process, meticulously refining the molecule to optimize its affinity and selectivity for EphA2. Each chemical modification sought to enhance pharmacodynamic properties while maintaining specificity, a critical factor for minimizing off-target effects and improving therapeutic indices. This rational drug design process exemplifies the intersection of medicinal chemistry and molecular biology driving next-generation cancer therapeutics.

Looking forward, Armida Labs is committed to advancing Targefrin through rigorous IND-enabling studies using the current SBIR funding. The primary focus is pancreatic cancer, one of the most lethal and treatment-resistant malignancies worldwide, underscoring the urgent need for novel therapeutic agents. Beyond pancreatic cancer, the scope of Targefrin’s application may extend to a wide range of EphA2-driven tumors, potentiating broad clinical impact.

The research team is optimistic about the translational potential of Targefrin and the implications for targeted therapy in metastatic disease. Pellecchia expressed enthusiasm: “Coming from an academic laboratory setting to startup verification embodies the spirit of translational medicine. With this funding, we are poised to move this innovative molecule closer to clinical reality.” He emphasized that additional support through fundraising will be vital to propel the molecule into early phase clinical trials.

Technical insights into Targefrin’s mode-of-action illustrate its distinction from traditional small-molecule inhibitors or monoclonal antibodies targeting receptor tyrosine kinases. Instead of competitive inhibition, Targefrin leverages induced receptor dimerization to hijack the natural receptor downregulation pathway, effectively removing the pro-tumorigenic receptor from the cancer cell architecture. This biological elegance represents an advanced modality in therapeutic design, addressing the unmet challenge of targeting overexpressed receptors in a ligand-deficient microenvironment.

The advancement of Targefrin is emblematic of a broader trend in oncology drug development focusing on protein degradation technologies, including proteolysis targeting chimeras (PROTACs) and similar modalities. Targefrin contributes to this evolving landscape by utilizing receptor dimerization-induced degradation, a less explored but highly promising avenue. If successful, this strategy may inspire novel approaches for other receptor-driven cancers.

Beyond the molecular frontiers, the initiative by Armida Labs underscores the critical role of academic-industry partnerships and government-funded innovation programs in accelerating cancer drug discovery. The SBIR grants exemplify how carefully structured funding mechanisms can bridge early-stage scientific discoveries with translational development, fostering the pipeline for novel therapeutics tailored to pressing clinical needs.

As Armida Labs moves forward, the oncology community will keenly watch the outcomes of these preclinical studies. The potential to transform metastatic cancer treatment could herald a new era where therapeutics not only inhibit tumor growth but also dismantle the cellular mechanisms facilitating metastasis, improving survival and quality of life for countless patients worldwide.

Subject of Research: Anti-metastatic therapy targeting EphA2 receptor in cancer using a dimeric peptide mimetic.
Article Title: Not provided.
News Publication Date: Not provided.
Web References:

• Armida Labs: http://armida-labs.com/
• UCR School of Medicine: https://profiles.ucr.edu/app/home/profile/maurizio
• Center for Molecular and Translational Medicine: https://molmed.ucr.edu/
• Armida Labs Team: https://www.armidalabs.com/armida-labs-team/carlo-baggio-ph-d
• UCR homepage: http://www.ucr.edu/
  Image Credits: Armida Labs, Inc.
  Keywords: Targefrin, EphA2, anti-metastatic agent, pancreatic cancer, receptor degradation, peptide mimetic, cancer metastasis, preclinical studies, SBIR grant, National Cancer Institute, molecular targeted therapy, peptide dimerization.

The project’s core ambition involves harnessing artificial intelligence (AI) to transform the way vaccine information is communicated to parents, aiming to dismantle the barriers that fuel hesitancy. With a robust $2.8 million grant from the National Cancer Institute, part of the National Institutes of Health, Nan and her interdisciplinary team are developing a personalized, AI-driven chatbot. This technology is engineered not only to provide accurate health information but to adapt dynamically to parents’ individual concerns, beliefs, and communication preferences in real time—offering a tailored conversational experience that traditional brochures and websites simply cannot match.

HPV vaccination has long struggled with public misconceptions, stigma, and misinformation that discourage uptake. A significant factor behind the reluctance is tied to the vaccine’s association with a sexually transmitted infection, which prompts some parents to believe their children are too young for the vaccine or that vaccination might imply premature engagement with sexual activity. This misconception, alongside a lack of tailored communication strategies, has contributed to persistent disparities in vaccination rates. These disparities are especially pronounced among men, individuals with lower educational attainment, and those with limited access to healthcare, as Professor Cheryl Knott, a public health behavioral specialist at UMD, highlights.

Unlike generic informational campaigns, the AI chatbot leverages cutting-edge natural language processing (NLP) to simulate nuanced human dialogue. However, it does so without succumbing to the pitfalls of generative AI models, such as ChatGPT, which can sometimes produce inaccurate or misleading answers. Instead, the system draws on large language models to generate a comprehensive array of possible responses. These are then rigorously curated and vetted by domain experts before deployment, ensuring that the chatbot’s replies remain factual, reliable, and sensitive to users’ needs. When interacting live, the chatbot analyzes parents’ input in real time, selecting the most appropriate response from this trusted set, thereby balancing flexibility with accuracy.

This “middle ground” model, as described by Philip Resnik, an MPower Professor affiliated with UMD’s Department of Linguistics and Institute for Advanced Computer Studies, preserves the flexibility of conversational AI while instituting “guardrails” to maintain scientific integrity. The approach avoids the rigidity of scripted chatbots that deliver canned, predictable replies; simultaneously, it steers clear of the “wild west” environment of fully generative chatbots, where the lack of control can lead to misinformation. Instead, it offers an adaptive yet responsible communication tool, capable of engaging parents on their terms while preserving public health objectives.

The first phase of this ambitious experiment emphasizes iterative refinement of the chatbot via a user-centered design process. This involves collecting extensive feedback from parents, healthcare providers, and community stakeholders to optimize the chatbot’s effectiveness and cultural sensitivity. Once this foundational work is complete, the team plans to conduct two rigorous randomized controlled trials. The first trial will be conducted online with a nationally representative sample of U.S. parents, compare the chatbot’s impact against traditional CDC pamphlets, and measure differences in vaccine acceptance. The second trial will take place in clinical environments in Baltimore, including pediatric offices, to observe how the chatbot influences decision-making in real-world healthcare settings.

Min Qi Wang, a behavioral health professor participating in the project, emphasizes that “tailored, timely, and actionable communication” facilitated by AI signals a paradigm shift in public health strategies. This shift extends beyond HPV vaccination, as such advanced communication systems possess the adaptability to address other complex public health challenges. By delivering personalized guidance directly aligned with users’ expressed concerns, AI can foster a more inclusive health dialogue that values empathy and relevance, which traditional mass communication methods often lack.

Beyond increasing HPV vaccination rates, the research team envisions broader implications for public health infrastructure. In an era where misinformation can spread rapidly and fear often undermines scientific recommendations, AI-powered tools offer a scalable, responsive mechanism to disseminate trustworthy information quickly. During future pandemics or emergent health crises, such chatbots could serve as critical channels for delivering customized, real-time guidance to diverse populations, helping to flatten the curve of misinformation while respecting individual differences.

The integration of AI chatbots into health communication represents a fusion of technological innovation with behavioral science, opening new horizons for personalized medicine and health education. By engaging users empathetically and responsively, these systems can build trust and facilitate informed decision-making, critical components of successful public health interventions. Professor Nan highlights the profound potential of this marriage between AI and public health communication by posing the fundamental question: “Can we do a better job with public health communication—with speed, scale, and empathy?” Project outcomes thus far suggest an affirmative answer.

As the chatbot advances through its pilot phases and into clinical trials, the research team remains committed to maintaining a rigorous scientific approach, ensuring that the tool’s recommendations align with the highest standards of evidence-based medicine. This careful balance between innovation and reliability is essential to maximize public trust and the chatbot’s ultimate impact on vaccine uptake. Should these trials demonstrate efficacy, the model could serve as a blueprint for deploying AI-driven communication tools across various domains of health behavior change.

Moreover, the collaborative nature of this project—bringing together communication experts, behavioral scientists, linguists, and medical professionals—illustrates the importance of interdisciplinary efforts in addressing complex health challenges. Each field contributes unique insights: linguistic analysis enables nuanced conversation design, behavioral science guides motivation and persuasion strategies, and medical expertise ensures factual accuracy and clinical relevance. This holistic framework strengthens the chatbot’s ability to resonate with diverse parent populations and to overcome entrenched hesitancy.

In conclusion, while HPV vaccines represent a major advancement in cancer prevention, their potential remains underutilized due to deeply embedded hesitancy fueled by stigma and misinformation. Leveraging AI-driven, personalized communication stands as a promising strategy to bridge this gap. The University of Maryland’s innovative chatbot project underscores the use of responsible artificial intelligence to meet parents where they are, addressing their unique concerns with empathy and scientific rigor. This initiative not only aspires to improve HPV vaccine uptake but also to pave the way for AI’s transformative role in future public health communication efforts.

Subject of Research: Artificial intelligence-enhanced communication to improve HPV vaccine uptake among parents.

Article Title: Transforming Vaccine Communication: AI Chatbots Target HPV Vaccine Hesitancy in Parents

News Publication Date: Information not provided in the source content.

Web References:
https://sph.umd.edu/people/cheryl-knott
https://sph.umd.edu/people/min-qi-wang

Image Credits: Credit: University of Maryland (UMD)

Keywords: Vaccine research, Science communication

The core objective of Dr. Gottschlich’s study, titled “Investigation of socio-genomic associations related to survival among a population-based sample of those diagnosed with endometrial cancer in Metropolitan Detroit,” is to unravel complex interactions between social determinants of health and biological factors that influence patient survival. Endometrial cancer, a gynecologic cancer affecting the uterine lining, presents with notably disparate survival rates among different demographic groups. Despite controlling for known biological and social variables, certain high-risk populations exhibit mortality rates that are double those of their counterparts, signaling the presence of underlying mechanisms yet to be understood.

This research utilizes a socio-genomic framework—a cutting-edge approach combining social epidemiology with molecular biology—to investigate how chronic social stress may biologically modulate cancer progression and survival outcomes. Socio-genomics explores the pathways through which environmental and psychosocial stressors can alter gene expression, immune function, and tumor biology. Dr. Gottschlich hypothesizes that chronic stress is a key modifier in the relationship between molecular subtypes of endometrial cancer and patient survival, proposing that stress-induced biological changes could partly explain racial and socio-economic disparities in mortality.

The study population is drawn from the Detroit Research on Cancer Survivors (ROCS) cohort, which is a longitudinal, population-based dataset comprising over 320 women diagnosed with endometrial cancer in the Metropolitan Detroit area. This cohort is particularly valuable due to its comprehensive data collection, which includes detailed annual surveys assessing psychosocial stressors, geocoded residential information, and longitudinal clinical records including vital statistics. The integration of these diverse data streams allows for robust analyses linking neighborhood-level stressors to molecular cancer profiles and survival trajectories.

By leveraging bioinformatics and molecular epidemiology techniques, Dr. Gottschlich’s research aims to delineate specific socio-genomic signatures that correlate with poorer outcomes. These signatures may include alterations in gene expression related to stress-response pathways, immune system modulation, and tumor aggressiveness. Uncovering these profiles could illuminate new biomarkers for early detection of high-risk patients and novel biological targets for therapeutic interventions designed to reduce disparities.

This award not only provides protected time for Dr. Gottschlich to deepen her expertise in molecular cancer epidemiology but also positions her to mentor the next generation of scientists working at the intersection of social health determinants and cancer biology. Her appointment at Wayne State University began recently, in September 2023, marking a significant milestone in her career dedicated to unraveling the biological underpinnings of health inequities.

The research holds transformative potential for public health and clinical oncology practices, especially within urban settings like Detroit, where socioeconomic and racial disparities are pronounced. Chronic stress, often stemming from systemic inequities such as economic deprivation, racial discrimination, and limited healthcare access, could be a mechanistic link escalating biological vulnerability in these populations. By elucidating this link, Dr. Gottschlich’s work underscores the importance of holistic cancer care that integrates social and molecular science.

Furthermore, findings gleaned from this exploratory study will set the stage for future, large-scale R01 grant applications that aim to deepen and expand this line of inquiry. These forthcoming projects could foster interdisciplinary collaborations, combining expertise in epidemiology, molecular biology, bioinformatics, and social sciences to develop comprehensive interventions that address both social and biological determinants of cancer survival.

Experts at Wayne State University, including Vice President for Research & Innovation Dr. Ezemenari M. Obasi, have expressed enthusiasm for the profound impact this project could have on cancer research and population health. Career development awards like this are essential for nurturing emerging leaders in biomedical science, ensuring continued innovation and the advancement of knowledge necessary to tackle complex health challenges.

The significance of this work resonates beyond academic circles. It challenges the traditional paradigms of cancer research by emphasizing the multifaceted interaction of social environments and genomic processes. Such interdisciplinary inquiry is poised to propel the field toward precision medicine approaches that account for social context alongside molecular tumor characteristics.

Detroit’s urban landscape, characterized by diverse demographic groups and varied socio-economic conditions, provides an ideal natural laboratory to study these complex dynamics. The outcomes of this project will offer valuable insights not only for local communities but also for national efforts aimed at reducing cancer health disparities and achieving health equity.

This research initiative embodies the mission of Wayne State University’s health sciences and research programs to address pressing health disparities through rigorous scientific inquiry and community engagement. Through this funding and Dr. Gottschlich’s leadership, a new frontier in understanding and mitigating cancer inequities is emerging—one that bridges molecular science with the social realities influencing patient survival.

Grant number CA303796 funds this vital research. It stands as a testament to the increasing recognition within the NIH of the importance of socio-genomic studies in transforming cancer outcomes and reducing long-standing health disparities affecting underserved populations.

Subject of Research: Epidemiology of cancer health disparities and socio-genomic factors affecting survival in endometrial cancer patients.

Article Title: National Cancer Institute Awards Dr. Anna Gottschlich $916,545 to Investigate Socio-Genomic Influences on Endometrial Cancer Survival

Image Credits: Wayne State University

Keywords: Cancer, Health Disparities, Epidemiology, Endometrial Cancer, Socio-genomics, Molecular Epidemiology, Bioinformatics, Chronic Stress, Cancer Equity

Tambre Leighn has been elevated to Chair of the NRG Patient Advocate Committee (PAC), building on her prior role as the committee’s Vice Chair. Ms. Leighn’s leadership across multiple committees within NRG Oncology, including the Cancer Care Delivery Research and Communications Committees, underscores her multifaceted contributions to the organization. Her professional background as a communications consultant, combined with her deeply personal mission stemming from founding her own firm, Well Beyond Ordinary, equips her uniquely to champion enhanced patient communication and engagement within oncology clinical trials.

In her new capacity as Chair, Ms. Leighn’s primary focus will be on expanding the reach and impact of the PAC within NRG’s expansive research network, which spans over a thousand sites internationally. By fostering collaboration between patient advocates and clinical researchers, she aims to refine trial protocols to better reflect patient needs, increase trial adherence, and optimize outcome measures. Her approach leans heavily on coaching-based interventions designed to empower patients, enhancing communication strategies that address adherence barriers and foster meaningful participation.

Working closely with Vice Chair Marlyn Molero, Ms. Leighn is spearheading initiatives to develop educational frameworks that systematically integrate patient advocacy into every stage of study design, execution, and publication. These efforts signal a transformative shift, positioning patients not merely as subjects of research but as active partners who can shape scientific inquiry and its translations into real-world clinical benefit.

While NRG Oncology continues to solicit applications for the now-vacant Vice Chair role on the PAC, these leadership shifts occur amid a burgeoning emphasis on interdisciplinary collaboration. The integration of patient advocacy within a research network focused on practice-changing oncology trials epitomizes a model where patient insights serve as catalysts for innovation, translational science, and personalized care strategies.

Simultaneously, Dr. Chris Holsinger has been appointed Surgical Vice Chair of the NRG Head and Neck Cancer (HNC) Committee and Chair of the NRG Head and Neck Surgery Working Group. Dr. Holsinger’s tenure with NRG Oncology exceeds two decades, marked by a consistent role in advancing surgical oncology research, particularly through his leadership in pivotal trials such as RTOG 0920, RTOG 1221, and ECOG 3311.

His contributions to surgical trial methodology are notable for pioneering prospective surgeon credentialing programs and ongoing quality assurance mechanisms. These innovative frameworks ensure surgical standardization and expertise across multiple collaborative group trials, which is critical in minimizing variability that might confound clinical outcomes in head and neck oncology studies. Dr. Holsinger’s dual role as an academic surgical oncologist and committee leader situates him as a key figure driving both scientific rigor and clinical relevance within the surgical research arena.

At Stanford University, where he serves as a professor and former Division Chief in the Department of Otolaryngology, Dr. Holsinger continues to intersect clinical practice, surgical robotics research, and artificial intelligence initiatives. His research portfolio reflects modern trends in precision surgical oncology, emphasizing the integration of technology-driven approaches to improve operative outcomes and multidisciplinary coordination in cancer care delivery.

Within NRG’s evolving leadership structure, Dr. Holsinger will collaborate with Committee Chair Dr. Sue Yom and Vice Chairs Drs. Stuart Wong and Neil Hayes to strategically expand the head and neck cancer research portfolio. This encompasses refining surgical trial design, enhancing data collection, and promoting surgeon engagement in the broader cooperative group context, further bridging subspecialty expertise with translational oncology.

These leadership appointments reinforce NRG Oncology’s foundational mission: to conduct multi-institutional, practice-changing clinical and translational research across a spectrum of adult cancers. Built upon the legacies of iconic trials groups including NSABP, RTOG, and GOG, the organization leverages a vast network of multidisciplinary investigators—medical oncologists, radiation oncologists, surgeons, pathologists, physicists, statisticians, and more. The breadth and depth of this collaborative infrastructure enable the conduct of complex, large-scale studies that inform standards of care globally.

Funding and infrastructure support from the National Cancer Institute empower NRG Oncology to design and execute clinical trials with specific emphases, such as gender-specific malignancies and localized or locally advanced tumors. The group’s integrated approach acknowledges the heterogeneity of cancer biology and patient populations, necessitating nuanced trial designs informed by highly engaged leadership in both patient advocacy and surgical innovation.

Ultimately, the appointments of Ms. Leighn and Dr. Holsinger symbolize a synergistic advancement for NRG Oncology, promoting pathways where patient-centered communication strategies and cutting-edge surgical research converge. As personalized oncology continues to evolve, such leadership ensures that multidisciplinary teams address not only the biological complexities of cancer but also the human elements essential to translating research into tangible improvements in patient outcomes.

NRG Oncology’s open call for leadership roles signals the ongoing opportunity for experts and advocates to shape the future directions of clinical trials research. Their commitment to transparent, inclusive, and innovative governance remains a cornerstone of their strategy to accelerate discoveries that revolutionize cancer treatment paradigms worldwide.

Subject of Research: Leadership appointments in clinical research committees focused on patient advocacy and surgical oncology within NRG Oncology.

Web References:
www.nrgoncology.org/Current-Openings
www.nrgoncology.org

Keywords: NRG Oncology, patient advocate leadership, surgical oncology, head and neck cancer, clinical trials, cancer research, patient-centered research, surgical credentialing, multidisciplinary oncology, translational research, National Cancer Institute, NCTN.